TW200904979A - Reoviruses having modified sequences - Google Patents

Reoviruses having modified sequences Download PDF

Info

Publication number
TW200904979A
TW200904979A TW097108636A TW97108636A TW200904979A TW 200904979 A TW200904979 A TW 200904979A TW 097108636 A TW097108636 A TW 097108636A TW 97108636 A TW97108636 A TW 97108636A TW 200904979 A TW200904979 A TW 200904979A
Authority
TW
Taiwan
Prior art keywords
leu
ser
ala
val
asp
Prior art date
Application number
TW097108636A
Other languages
English (en)
Chinese (zh)
Inventor
Matthew C Coffey
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39758956&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200904979(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of TW200904979A publication Critical patent/TW200904979A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/765Reovirus; Rotavirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13Tumour cells, irrespective of tissue of origin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12211Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12221Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12211Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12211Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW097108636A 2007-03-12 2008-03-12 Reoviruses having modified sequences TW200904979A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89442507P 2007-03-12 2007-03-12
US98956807P 2007-11-21 2007-11-21

Publications (1)

Publication Number Publication Date
TW200904979A true TW200904979A (en) 2009-02-01

Family

ID=39758956

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097108636A TW200904979A (en) 2007-03-12 2008-03-12 Reoviruses having modified sequences

Country Status (16)

Country Link
US (5) US7803385B2 (enExample)
EP (2) EP2132315B1 (enExample)
JP (1) JP5577103B2 (enExample)
KR (1) KR101647843B1 (enExample)
CN (1) CN103710359A (enExample)
AR (1) AR066395A1 (enExample)
AU (1) AU2008226291B2 (enExample)
CA (1) CA2678721C (enExample)
DK (1) DK2132315T3 (enExample)
ES (1) ES2548442T3 (enExample)
IL (4) IL200353A (enExample)
MX (2) MX2009009598A (enExample)
SG (1) SG191602A1 (enExample)
TW (1) TW200904979A (enExample)
WO (1) WO2008110004A1 (enExample)
ZA (1) ZA200905951B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
EP2132315B1 (en) 2007-03-12 2015-07-15 Oncolytics Biotech Inc. Reoviruses having modified sequences
CA2699805A1 (en) * 2007-10-22 2009-04-30 Oncolytics Biotech Inc. Treatment regime for proliferative disorders
WO2009143611A1 (en) * 2008-05-27 2009-12-03 Oncolytics Biotech Inc. Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
CA2723580A1 (en) * 2008-05-27 2009-12-03 Oncolytics Biotech Inc. Modulating interstitial pressure and oncolytic viral delivery and distribution
BRPI0910185A2 (pt) * 2008-06-26 2015-12-01 Ceva Sante Animale S A sorotipo de reovírus aviário isolado, reovírus aviário isolado, peptídeos, vacina, antisoro isolado, anticorpo isolado, método para proteção de aves, método para detecção ou quantificação de reovírus em aves, recipiente para vacinação de aves, kit para vacinação de aves, kit de diagnóstico, linhagem celular derivada da lmh
FR2939807B1 (fr) * 2008-12-11 2010-12-17 Biomerieux Sa Nouveau reovirus isole, procedes et kits de detection
US9395356B2 (en) * 2009-10-02 2016-07-19 The National Veterinary Institute Piscine reovirus immunogenic compositions
SG190419A1 (en) 2010-12-02 2013-06-28 Oncolytics Biotech Inc Lyophilized viral formulations
EP2646051A4 (en) * 2010-12-02 2014-05-28 Oncolytics Biotech Inc FORMULATIONS OF LIQUID VIRUSES
CN103492557B (zh) * 2011-04-29 2015-07-29 昂科利蒂克斯生物科技公司 使用凝胶渗透色谱法纯化病毒的方法
ES2796950T3 (es) * 2013-11-15 2020-11-30 Oncolytics Biotech Inc Virus oncolíticos y regímenes reforzados para tratamiento de cáncer
US9660989B1 (en) 2014-01-31 2017-05-23 Google Inc. Internet-wide identity management widget
EA201891848A1 (ru) 2016-02-16 2019-02-28 Осака Юниверсити Фармацевтическая композиция для применения в лечении фиброза
WO2019237063A1 (en) * 2018-06-07 2019-12-12 Emory University Modified reoviruses, particles, and uses in treating proliferative disorders
KR102401077B1 (ko) 2019-01-25 2022-05-24 바이로큐어 주식회사 다람쥐 섬유종 바이러스 및 리오바이러스를 포함하는 암 예방 또는 치료용 약학적 조성물
US20220193220A1 (en) * 2019-05-03 2022-06-23 Kansas State University Research Foundation Immunogenic compositions for novel reassortant mammalian ortheovirus from pigs
EP4268837A4 (en) * 2020-12-22 2025-05-07 Virocure, Inc. NEW MODIFIED REOVIRUS AND ITS USE
US20240041959A1 (en) * 2020-12-22 2024-02-08 Virocure, Inc. Novel modified reovirus and use thereof
WO2023048532A1 (ko) * 2021-09-24 2023-03-30 바이로큐어 주식회사 레오바이러스 기반 신규한 백신플랫폼 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
AU1202202A (en) * 2000-11-09 2002-05-21 Oncolytics Biotech Inc Methods for the treatment of cellular proliferative disorders
WO2002043647A2 (en) 2000-12-01 2002-06-06 University Of Ottawa Oncolytic virus
EP1370643A1 (en) * 2001-03-16 2003-12-17 Oncolytics Biotech, Inc. Method of extracting virus from cell culture
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
AU2005257107A1 (en) 2004-06-24 2006-01-05 Dnavec Research Inc. Anticancer agent containing dendritic cell having RNA virus transferred thereinto
CA2617600A1 (en) * 2005-08-01 2007-09-07 University Technologies International, Inc. Attenuated reovirus
WO2008009115A1 (en) 2006-07-18 2008-01-24 Ottawa Health Research Institute Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses
EP2132315B1 (en) 2007-03-12 2015-07-15 Oncolytics Biotech Inc. Reoviruses having modified sequences
WO2009143611A1 (en) * 2008-05-27 2009-12-03 Oncolytics Biotech Inc. Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
EP2646051A4 (en) * 2010-12-02 2014-05-28 Oncolytics Biotech Inc FORMULATIONS OF LIQUID VIRUSES
SG190419A1 (en) * 2010-12-02 2013-06-28 Oncolytics Biotech Inc Lyophilized viral formulations

Also Published As

Publication number Publication date
US8691241B2 (en) 2014-04-08
IL221701A0 (en) 2012-10-31
US7803385B2 (en) 2010-09-28
IL221700A0 (en) 2012-10-31
HK1132761A1 (en) 2010-03-05
CA2678721C (en) 2018-02-13
US20180344853A1 (en) 2018-12-06
AR066395A1 (es) 2009-08-19
AU2008226291B2 (en) 2014-01-16
ES2548442T3 (es) 2015-10-16
US11246930B2 (en) 2022-02-15
KR20090125103A (ko) 2009-12-03
AU2008226291A1 (en) 2008-09-18
CA2678721A1 (en) 2008-09-18
SG191602A1 (en) 2013-07-31
AU2008226291A2 (en) 2009-10-08
MX346950B (es) 2017-04-06
MX2009009598A (es) 2009-09-21
DK2132315T3 (en) 2015-10-19
IL221702A0 (en) 2012-10-31
KR101647843B1 (ko) 2016-08-11
CN103710359A (zh) 2014-04-09
WO2008110004A1 (en) 2008-09-18
US20140186301A1 (en) 2014-07-03
JP5577103B2 (ja) 2014-08-20
US20080226602A1 (en) 2008-09-18
EP2132315B1 (en) 2015-07-15
US20200237917A1 (en) 2020-07-30
EP2952583A1 (en) 2015-12-09
US20110020288A1 (en) 2011-01-27
US10596260B2 (en) 2020-03-24
IL200353A0 (en) 2011-08-01
ZA200905951B (en) 2010-11-24
EP2132315A1 (en) 2009-12-16
JP2010520758A (ja) 2010-06-17
EP2132315A4 (en) 2011-10-05
US20090035278A2 (en) 2009-02-05
IL200353A (en) 2017-07-31
US10039827B2 (en) 2018-08-07

Similar Documents

Publication Publication Date Title
TW200904979A (en) Reoviruses having modified sequences
Koch et al. The molecular biology of poliovirus
TWI317378B (en) Improved viral purification methods
CN105407872B (zh) 噬菌体的应用
TW200951143A (en) Modulating interstitial pressure and oncolytic viral delivery and distribution
EP2016094A1 (en) Novel analogues of antimicrobial and anticancer peptide synthesized and produced from gaegurin 5
WO2023040834A1 (zh) 一株羊驼源纳米抗体及其应用
CN101899466B (zh) 登革病毒-日本脑炎病毒嵌合假病毒疫苗及其制备方法
CN117752693A (zh) 没食子提取物在制备防治猪流行性腹泻药物中的应用
KR102277435B1 (ko) 소라페닙 저항성 간암 치료용 조성물 및 소라페닙 내성 간암 치료에 대한 정보 제공 방법
TW200950777A (en) Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
CN102617596B (zh) 二倍半萜类化合物黑珀萜i及其制备方法和用途
TW201020546A (en) An antigenic peptide of grouper iridovirus and use thereof
TWI377950B (en) Use of an anti-bacterial peptide for treating cancer
HK1132761B (en) Reoviruses having modified sequences
CN101480391B (zh) 槐果碱在制备治疗由柯萨奇a病毒所引起疾病的药物中的应用
AU2013201835A1 (en) Reoviruses having modified sequences